Venture Corporation - Phillip Securities 2025-08-07: Coping Under Challenging Conditions

• Venture Corp’s outlook commentary shared little on near-term operating conditions. The company emphasised its long-term relationship, investments, and strong balance sheet.
• Nevertheless, we believe Venture Corp's 2H25 earnings will remain weak –
  1. - Read this at SGinvestors.io -
  2. uncertainty over drug pricing has scaled back big pharma capex; and
  3. cuts in US research funding grants further pulling down demand for life science equipment.
• 1H25 results were within expectations. Revenue and PATMI were 51%/49% of FY25e expectations. 1H25 PATMI net profit declined 8.6% y-o-y to S$112.9mil, in-line with revenue contracting 8.8%.
• A special special dividend of 5 cents was announced in addition to an unchanged interim dividend of 25 cents.

The Positive

Ample cash.

• - Read this at SGinvestors.io -
• There will be two new innovation centres in China and the US to source fast-growing product opportunities.

The Negative

Consumer lifestyle products decline.

• Read more at SGinvestors.io.

Above is an excerpt from a report by Phillip Securities Research.
Clients of Phillip Capital may be the first to access the full PDF report @ https://www.stocksbnb.com/.

Previous report by Phillip:
2025-05-15 Venture Corp - 2025 Looks Tough.

Price targets by 3 other brokers at Venture Corp Target Prices.

Listing of research reports at Venture Corp Analyst Reports.

Relevant links:
Venture Corp Share Price History,
Venture Corp Announcements,
Venture Corp Dividend Payout Dates & Corporate Actions,
Venture Corp News